We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+18.34%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$261M
AUM Growth
-$25M
(-8.7%)
Cap. Flow
-$67.9M
Cap. Flow
% of AUM
-26.04%
Top 10 Holdings %
Top 10 Hldgs %
67.6%
Holding
31
New
10
Increased
1
Reduced
16
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Steris
STE
|
+$13M |
| 2 |
HOLX
Hologic
HOLX
|
+$11.6M |
| 3 |
Pacira BioSciences
PCRX
|
+$9.34M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$5.58M |
| 5 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$3.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$25.1M |
| 2 |
Quest Diagnostics
DGX
|
+$13.8M |
| 3 |
Alkermes
ALKS
|
+$10.4M |
| 4 |
ELGX
Endologix Inc
ELGX
|
+$10.2M |
| 5 |
NXTM
NxStage Medical Inc.
NXTM
|
+$8.92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.74% |
| 2 | Technology | 7.03% |
| 3 | Communication Services | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MODN
26
DELISTED
MODEL N, INC.
MODN
| $267K | 0.1% |
+20,000
| New | +$235K |
|
27
State Street SPDR S&P 500 ETF Trust
SPY
$781B
| $123K | 0.05% |
+3,000
| New | +$622K |
|
28
PUT
iShares S&P 100 ETF
OEF
$19.8B
| – | – |
-7,000
| Closed | -$518K |
|
|
29
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$781B
| – | – |
-1,000
| Closed | -$18K |
|
|
XENT
30
DELISTED
Intersect ENT, Inc
XENT
| – | – |
-225,000
| Closed | -$4.28M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2016 Portfolio in Review
As of Q2 2016, Tamarack Advisers held 31 positions worth $261M, down 8.7% from $286M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Tamarack Advisers withdrew a net $67.9M in Q2 2016, closing 3 positions and reducing 16 holdings. Its most notable exit was Intersect ENT, Inc, an estimated $4.28M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 80% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Tamarack Advisers opened a new position in Steris worth $12.7M.
- Tamarack Advisers's largest Q2 2016 buy was Steris: 185,000 shares worth $12.7M.
- Tamarack Advisers added most to Ariad Pharmaceuticals Inc in Q2 2016, an estimated $3.75M increase.
- Tamarack Advisers's biggest Q2 2016 reduction was Patterson Companies, Inc., cutting an estimated $25.1M.
- Tamarack Advisers fully exited Intersect ENT, Inc in Q2 2016, selling an estimated $4.28M.
- Tamarack Advisers's ten largest holdings make up 68% of its $261M portfolio in Q2 2016.
- Tamarack Advisers opened 10 new positions and closed 3 in Q2 2016.
- Tamarack Advisers's portfolio value fell 8.7% quarter-over-quarter to $261M.
Based on Tamarack Advisers's 13F filing for Q2 2016, filed 15 Aug 2016.